USE OF BROMODOMAIN-CONTAINING PROTEIN 9 ANTAGONISTS IN COMBINATION WITH VITAMIN D RECEPTOR AGONISTS IN DIABETES TREATMENT

摘要

Methods are provided for reducing blood glucose, which utilize an agent that increases the biological activity of a vitamin D receptor (VDR) (e.g., a VDR agonist), in combination with an antagonist of bromodomain-containing protein 9 (BRD9). IN some examples, such methods treat type II diabetes.